Exagen Inc. to Participate in Fourth Quarter Investor Conferences

XGN 11.13.2024

Full Press ReleaseSEC FilingsOur XGN Tweets

About Gravity Analytica

Recent News

  • 01.12.2025 - Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
  • 12.12.2024 - Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
  • 11.21.2024 - CG MedTech, Diagnostics and Digital Health & Services Forum

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 12.12.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

CARLSBAD, Calif.,Nov. 13, 2024(GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences:

Canaccord Genuity MedTech, Diagnostics andDigital Health & Services Forum

Company presentation byJohn Aballi, President and CEO onThursday, November 21, 2024, at3:00 p.m. ESTat theWestin NY Grand Central Hotel. Management will also participate in one-on-one investor meetings.

Evercore HEALTHCONx Conference

Company presentation byJohn Aballi, President and CEO onWednesday, December 4, 2024, at12:30 p.m. ESTatThe Lowes Coral Gables HotelinCoral Gables, FL.Management will also participate in one-on-one investor meetings.

TD Cowen Diagnosing Tomorrow Conference– Tools and Technologies for the Next Decade

John Aballi, President and CEO, with participate in a panel discussion titled:Beyond CanceronThursday, December 12, 2024, at2:40 p.m. ESTat One Vanderbilt, 20thFloor,New York, NY.

About Exagen Inc.

Exagen Inc.(Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based inSan Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care,Exagenis dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visitExagen.comor follow @ExagenInc onX.

Exagen Inc.Ryan DouglasIR@exagen.com760.560.1525

Primary Logo

Source: Exagen Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com